Trial Profile

Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zoledronic acid (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
Indications Breast cancer
Focus Therapeutic Use
Acronyms NEOZOL

Most Recent Events

12 Dec 2015 Status changed from completed to discontinued according to results presented at the 38th Annual San Antonio Breast Cancer Symposium.
12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
19 Sep 2013 Planned end date changed from 1 Nov 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com